Axa
VYNE icon

Axa’s VYNE Therapeutics VYNE Stock Holding History

Axa’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,702
Closed -$423K – 1332
2021
Q2 		$423K Sell
6,702
-42,305
-86% -$3.35M ﹤0.01% 1125
2021
Q1 		$6.04M Sell
49,007
-3,701
-7% -$537K 0.02% 659
2020
Q4 		$6M Buy
52,708
+877
+2% +$110K 0.02% 651
2020
Q3 		$6.2M Buy
51,831
+574
+1% +$67K 0.02% 567
2020
Q2 		$6.38M Buy
51,257
+40,524
+378% +$5.49M 0.03% 545
2020
Q1 		$2.07M Buy
+10,733
New +$3.37M 0.01% 728

Other funds holding VYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Axa's VYNE Position: Q3 2021 in Review

Axa sold out of VYNE Therapeutics (VYNE) in Q3 2021, closing a stake of 6,702 shares — an estimated $423K sold.

Axa first reported a position in VYNE in Q1 2020 and held it in 6 quarters. The position peaked at $6.38M in Q2 2020. 64 funds tracked by Wall St. Rank hold VYNE as of Q3 2021.

  • Axa reported no remaining VYNE Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Axa sold 6,702 VYNE Therapeutics shares in Q3 2021, an estimated $423K.
  • Axa first reported a position in VYNE Therapeutics in Q1 2020 and held it in 6 quarters.
  • Axa's VYNE Therapeutics position peaked at $6.38M in Q2 2020.
  • 64 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2021.

Based on Axa's 13F filing for Q3 2021, filed 15 Nov 2021.